Euros Hartley Report | 29 April 2022
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s March quarterly report.
Eurox Hartleys Report | 28 April 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s announcement that the US FDA has granted BOT Qualified Infectious Disease Product (QIPD) designation for BTX1801.
Euroz Hartleys Report | 1 April 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s announcement that it had appointed executives, Howie McKibbon, Chief Commercial Officer (CCO) and Dr Patricia Walker, Chief Medical Officer (CMO).
Euroz Hartleys Report | 28 March 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s announcement that it had received an R&D tax incentive refund of $2.75m.
Euroz Hartleys Report | 1 March 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly update.
Analyst Seth Lizee commented:
“The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically successful, is huge.”
ShareCafe ‘Hidden Gems’ Webinar
/in Featured, News, Presentations /by Haley ChartresBotanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.
His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.
Euroz Hartleys Report | 28 January 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly report.
2022 is described as “a big year ahead”.
2022 Edison Open House: Global Healthcare
/in Featured, Latest News, News /by Haley ChartresBotanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.
Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.
Click here to register, it’s free.
Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.
DEAL NEWS | Pfizer enters CBD market
/in Featured, News /by Haley ChartresAt Botanix, we genuinely believe in the therapeutic potential of CBD to treat serious medical conditions … and clearly we’re not alone.
Last month, pharmaceutical company Pfizer announced its entry into the cannabinoid space after sharing news of its planned acquisition of clinical-stage company Arena Pharmaceuticals for a total equity value of around US$6.7 billion.
According to the official press release from Pfizer, Arena holds a ‘diverse and promising’ portfolio, including an innovative CB2 agonist and dermatological disease candidate.
AMR: the next global pandemic?
/in Featured, News /by Haley ChartresWhile the world continues to battle COVID-19, experts are concerned that older, sick and vulnerable patients may be at increased risk of AMR. According to an article in The Lancet, 1 in 7 patients hospitalised with COVID-19 have “acquired a dangerous secondary bacterial infection, and 50% of patients who have died had such infections.”
At Botanix, we are exploring the potential of synthetic CBD to develop novel therapies to address AMR, and ultimately reduce the dependence on broad-spectrum antibiotics.
